tetano
Editor, Senior Moderator
Metabolites
. 2021 Dec 6;11(12):847.
doi: 10.3390/metabo11120847.
Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate
Elettra Barberis[SUP] 1 2 [/SUP], Elia Amede[SUP] 1 2 [/SUP], Shahzaib Khoso[SUP] 1 2 [/SUP], Luigi Castello[SUP] 1 3 4 [/SUP], Pier Paolo Sainaghi[SUP] 1 3 [/SUP], Mattia Bellan[SUP] 1 3 [/SUP], Piero Emilio Balbo[SUP] 3 [/SUP], Giuseppe Patti[SUP] 1 3 [/SUP], Diego Brustia[SUP] 3 [/SUP], Mara Giordano[SUP] 3 5 [/SUP], Roberta Rolla[SUP] 3 5 [/SUP], Annalisa Chiocchetti[SUP] 2 5 [/SUP], Giorgia Romani[SUP] 3 [/SUP], Marcello Manfredi[SUP] 1 2 [/SUP], Rosanna Vaschetto[SUP] 1 3 [/SUP]
Affiliations
Abstract
Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath's biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.
Keywords: COVID-19; GCxGC-MS; breath analysis; metabolomics; noninvasive analysis.
. 2021 Dec 6;11(12):847.
doi: 10.3390/metabo11120847.
Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate
Elettra Barberis[SUP] 1 2 [/SUP], Elia Amede[SUP] 1 2 [/SUP], Shahzaib Khoso[SUP] 1 2 [/SUP], Luigi Castello[SUP] 1 3 4 [/SUP], Pier Paolo Sainaghi[SUP] 1 3 [/SUP], Mattia Bellan[SUP] 1 3 [/SUP], Piero Emilio Balbo[SUP] 3 [/SUP], Giuseppe Patti[SUP] 1 3 [/SUP], Diego Brustia[SUP] 3 [/SUP], Mara Giordano[SUP] 3 5 [/SUP], Roberta Rolla[SUP] 3 5 [/SUP], Annalisa Chiocchetti[SUP] 2 5 [/SUP], Giorgia Romani[SUP] 3 [/SUP], Marcello Manfredi[SUP] 1 2 [/SUP], Rosanna Vaschetto[SUP] 1 3 [/SUP]
Affiliations
- PMID: 34940605
- DOI: 10.3390/metabo11120847
Abstract
Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath's biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.
Keywords: COVID-19; GCxGC-MS; breath analysis; metabolomics; noninvasive analysis.